Human GDP-mannose 4,6 dehydratase

Abstract

The invention provides a novel GDP-mannose 4,6-dehydratase.

1 - 20 . (canceled)  
     
     
         21 . A method for treating a subject having a disorder characterized by aberrant cellular fucosylation comprising administering to the subject a therapeutically effective amount of an antibody capable of binding to: 
 (a) SEQ ID NO:2    (b) SEQ ID NO:3; or    (c) a fragment of (a) or (b) having GM4,6D activity.    
     
     
         22 . The method of  claim 21 , wherein the disorder is characterized by excessive cellular fucosylation.  
     
     
         23 . The method of  claim 22 , wherein the antibody is a monoclonal antibody.  
     
     
         24 . The method of  claim 22 , wherein the antibody is a polyclonal antibody.  
     
     
         25 . The method of  claim 22 , wherein the antibody is capable of binding to SEQ ID NO:2.  
     
     
         26 . The method of  claim 22 , wherein the antibody is capable of binding to SEQ ID NO:3.  
     
     
         27 . The method of  claim 22 , wherein the disorder is arthritis.  
     
     
         28 . The method of  claim 22 , wherein the disorder is transplant rejection.  
     
     
         29 . The method of  claim 22 , wherein the disorder is asthma.  
     
     
         30 . The method of  claim 22 , wherein the disorder is sepsis.  
     
     
         31 . The method of  claim 22 , wherein the disorder is reperfusion injury.  
     
     
         32 . The method of  claim 22 , wherein the disorder is stroke.  
     
     
         33 . The method of  claim 22 , wherein the disorder is infection  
     
     
         34 . The method of  claim 21 , wherein the disorder is characterized by reduced cellular fucosylation.  
     
     
         35 . The method of  claim 34 , wherein the disorder is Leukocyte deficiency type II.  
     
     
         36 . A method for inhibiting cellular fucosylation in a subject comprising administering to the subject a therapeutically effective amount of an antibody capable of binding to: 
 (a) SEQ ID NO:2    (b) SEQ ID NO:3; or    (c) a fragment of (a) or (b) having GM4,6D activity.    
     
     
         37 . The method of  claim 36 , wherein the antibody is a monoclonal antibody.  
     
     
         38 . The method of  claim 36 , wherein the antibody is a polyclonal antibody.  
     
     
         39 . The method of  claim 36 , wherein the antibody is capable of binding to SEQ ID NO:2.  
     
     
         40 . The method of  claim 36 , wherein the antibody is capable of binding to SEQ ID NO:3.